Placebo + IBI362
Phase 2Recruiting 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metabolic Dysfunction-associated Steatohepatitis (MASH)
Conditions
Metabolic Dysfunction-associated Steatohepatitis (MASH)
Trial Timeline
Jul 1, 2025 → Jul 22, 2027
NCT ID
NCT06937749About Placebo + IBI362
Placebo + IBI362 is a phase 2 stage product being developed by Innovent Biologics for Metabolic Dysfunction-associated Steatohepatitis (MASH). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06937749. Target conditions include Metabolic Dysfunction-associated Steatohepatitis (MASH).
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07255209 | Phase 3 | Recruiting |
| NCT06937749 | Phase 2 | Recruiting |
| NCT05607680 | Phase 3 | Completed |
Competing Products
20 competing products in Metabolic Dysfunction-associated Steatohepatitis (MASH)